The therapeutic relevance of a BRCA2 mutation in a patient with recurrent thymoma: a case report.

A potential role of poly (ADP-ribose) polymerase (PARP) inhibitors versus cytotoxic chemotherapy for treatment of -mutated recurrent thymoma merits discussion. However, due to the absence of data to support the functional and therapeutic significance of mutations in patients with thymoma, the potential for severe toxicity associated with PARP inhibitors, and availability of other safe and effective alternatives, other treatment options should be considered. PARP inhibitors can be considered for treatment of -mutated thymomas as part of a clinical trial or when other treatment options have been exhausted.